{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:17:42Z","timestamp":1790630262295,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"am","delay-in-days":379,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.therap.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T11:37:40Z","timestamp":1581593860000},"page":"195-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Update on bradykinin-mediated angioedema in 2020"],"prefix":"10.1016","volume":"75","author":[{"given":"Marion","family":"Lepelley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bernardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Defendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Crochet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Mallaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0390","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","article-title":"Angiotensin-converting enzyme inhibitor and other drug-associated angioedema","volume":"37","author":"Stone","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"10","key":"10.1016\/j.therap.2020.02.011_bib0395","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1111\/bph.14166","article-title":"The role of bradykinin receptor type 2 in spontaneous extravasation in mice skin: implications for non-allergic angio-oedema","volume":"175","author":"Bisha","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.therap.2020.02.011_bib0400","doi-asserted-by":"crossref","first-page":"76","DOI":"10.20452\/pamw.3273","article-title":"Bradykinin-mediated angioedema","volume":"126","author":"Obtu\u0142owicz","year":"2016","journal-title":"Pol Arch Med Wewn"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0405","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1054\/npep.2000.0823","article-title":"Neurokinin mediation of edema and inflammation","volume":"34","author":"Campos","year":"2000","journal-title":"Neuropeptides"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0410","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1124\/jpet.103.064105","article-title":"The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat","volume":"309","author":"Sulpizio","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.SRJ05001X","article-title":"The kallikrein-kinin system: current and future pharmacological targets","volume":"99","author":"Moreau","year":"2005","journal-title":"J Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.therap.2020.02.011_bib0420","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0196-9781(96)00201-X","article-title":"Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts","volume":"17","author":"Russell","year":"1996","journal-title":"Peptides"},{"issue":"12","key":"10.1016\/j.therap.2020.02.011_bib0425","first-page":"1443","article-title":"Unnecessary abdominal interventions in patients with hereditary angioedema","volume":"16","author":"Hahn","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0430","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/75.4.349","article-title":"Asphyxiation by laryngeal edema in patients with hereditary angioedema","volume":"75","author":"Bork","year":"2000","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0435","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1001\/archinte.161.5.714","article-title":"Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema","volume":"161","author":"Bork","year":"2001","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0440","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jaci.2012.05.055","article-title":"Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency","volume":"130","author":"Bork","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.therap.2020.02.011_bib0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2014.03.003","article-title":"Upper airway edema in 43 patients with hereditary angioedema","volume":"112","author":"Xu","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.therap.2020.02.011_bib0450","first-page":"6363787","article-title":"Consequences of misdiagnosed and mismanaged hereditary angioedema laryngeal attacks: an overview of cases from the Romanian registry","volume":"2018","author":"Moldovan","year":"2018","journal-title":"Case Rep Emerg Med"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0455","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/cea.13297","article-title":"Bradykinin mechanism is the main responsible for death by isolated asphyxiating angioedema in France","volume":"49","author":"Crochet","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2500\/aap.2013.34.3623","article-title":"HAE update: epidemiology and burden of disease","volume":"34","author":"Bernstein","year":"2013","journal-title":"Allergy Asthma Proc"},{"issue":"13","key":"10.1016\/j.therap.2020.02.011_bib0465","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.molimm.2010.05.010","article-title":"The plasma bradykinin-forming pathways and its interrelationships with complement","volume":"47","author":"Kaplan","year":"2010","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WOX.0b013e318216b7b2","article-title":"Bradykinin and the pathogenesis of hereditary angioedema","volume":"4","author":"Kaplan","year":"2011","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0475","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/ped.2014.0425","article-title":"Pathophysiology of hereditary angioedema","volume":"27","author":"Caccia","year":"2014","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0480","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1172\/JCI115175","article-title":"Synthesis of C1 inhibitor in fibroblasts from patients with type I and type II hereditary angioneurotic edema","volume":"87","author":"Kramer","year":"1991","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0485","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/humu.20197","article-title":"Hereditary angioedema: the mutation spectrum of SERPING1\/C1NH in a large Spanish cohort","volume":"26","author":"Roche","year":"2005","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0490","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.iac.2006.08.002","article-title":"Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management","volume":"26","author":"Zingale","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"issue":"9","key":"10.1016\/j.therap.2020.02.011_bib0495","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.4049\/jimmunol.152.9.4680","article-title":"Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor","volume":"152","author":"Mandle","year":"1994","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.therap.2020.02.011_bib0500","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/1529-0131(200108)44:8<1836::AID-ART321>3.0.CO;2-Y","article-title":"A new type of acquired C1 inhibitor deficiency associated with systemic lupus erythematosus","volume":"44","author":"Cacoub","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0505","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/all.13270","article-title":"Hereditary angioedema with a mutation in the plasminogen gene","volume":"73","author":"Bork","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0510","doi-asserted-by":"crossref","first-page":"484.e1","DOI":"10.1016\/j.ajog.2008.04.034","article-title":"Disease expression in women with hereditary angioedema","volume":"199","author":"Bouillet","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0515","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/iid3.137","article-title":"Hereditary angioedema with normal C1 inhibitor in a French cohort: clinical characteristics and response to treatment with icatibant","volume":"5","author":"Bouillet","year":"2017","journal-title":"Immun Inflamm Dis"},{"issue":"11","key":"10.1016\/j.therap.2020.02.011_bib0520","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/all.13543","article-title":"Plasminogen gene mutation with normal C1 inhibitor hereditary angioedema: three additional French families","volume":"73","author":"Belb\u00e9zier","year":"2018","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0525","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5644\/ama2006-124.210","article-title":"The incidence and frequency of various causes of angioedema in emergency medicine","volume":"47","author":"Karad\u017ea-Lapi\u0107","year":"2018","journal-title":"Acta Medica Acad"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0530","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00105-017-4119-9","article-title":"Drug-induced angioedema: focus on bradykinin","volume":"69","author":"Sachs","year":"2018","journal-title":"Hautarzt Z Dermatol Venerol Verwandte Ge"},{"issue":"8","key":"10.1016\/j.therap.2020.02.011_bib0535","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM200208223470820","article-title":"Bradykinin-mediated angioedema","volume":"347","author":"Nussberger","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0540","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.therap.2020.02.011_bib0545","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","author":"Miller","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0550","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0555","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","article-title":"An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors","volume":"10","author":"Morimoto","year":"2004","journal-title":"J Eval Clin Pract"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0560","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2222.2009.03323.x","article-title":"Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors","volume":"40","author":"Hoover","year":"2010","journal-title":"Clin Exp Allergy J"},{"issue":"7","key":"10.1016\/j.therap.2020.02.011_bib0565","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.1988.03410070095035","article-title":"Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition","volume":"260","author":"Slater","year":"1988","journal-title":"JAMA"},{"issue":"6832","key":"10.1016\/j.therap.2020.02.011_bib0570","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/bmj.304.6832.941","article-title":"Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors","volume":"304","author":"Hedner","year":"1992","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0575","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1345\/aph.1D458","article-title":"Intermittent visceral edema induced by long-term enalapril administration","volume":"38","author":"Orr","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"11","key":"10.1016\/j.therap.2020.02.011_bib0580","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/HJH.0b013e32834b4b9b","article-title":"Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema","volume":"29","author":"Beltrami","year":"2011","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0585","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399813666170214113856","article-title":"Dipeptidyl peptidase-4 inhibitor induced angioedema\u00a0\u2014\u00a0an overlooked and potentially lethal adverse drug reaction?","volume":"14","author":"Scott","year":"2018","journal-title":"Curr Diabetes Rev"},{"issue":"2\u00a0Pt\u00a02","key":"10.1016\/j.therap.2020.02.011_bib0590","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/hy0202.103054","article-title":"Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema","volume":"39","author":"Lefebvre","year":"2002","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0595","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","article-title":"Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema","volume":"54","author":"Brown","year":"2009","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0600","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am J Hypertens"},{"issue":"7","key":"10.1016\/j.therap.2020.02.011_bib0605","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1161\/STROKEAHA.116.013334","article-title":"Orolingual angioedema during or after thrombolysis for cerebral ischemia","volume":"47","author":"Myslimi","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.therap.2020.02.011_bib0610","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fmed.2018.00195","article-title":"Impact of bradykinin generation during thrombolysis in ischemic stroke","volume":"5","author":"Gauberti","year":"2018","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0615","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2515\/therapie\/2013071","article-title":"Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents","volume":"69","author":"Grandeau","year":"2014","journal-title":"Therapie"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0620","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2215\/CJN.07371009","article-title":"Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients","volume":"5","author":"Duerr","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0625","first-page":"1068","article-title":"Isolated angioedema: an overview of clinical features and etiology","volume":"17","author":"Nedelea","year":"2019","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0630","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1572-0241.2006.00492.x","article-title":"Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency","volume":"101","author":"Bork","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0635","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1148\/radiol.2532080598","article-title":"Case 151: hereditary angioedema in the duodenum","volume":"253","author":"Courtier","year":"2009","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.therap.2020.02.011_bib0640","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/MCG.0b013e31829e7edf","article-title":"Gastrointestinal manifestations, diagnosis, and management of hereditary angioedema","volume":"47","author":"Jalaj","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.therap.2020.02.011_bib0645","first-page":"925861","article-title":"Hereditary angioedema and gastrointestinal complications: an extensive review of the literature","volume":"2015","author":"Patel","year":"2015","journal-title":"Case Rep Immunol"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0650","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lpm.2014.09.012","article-title":"Emergency management of bradykinin-mediated angioedema","volume":"44","author":"Floccard","year":"2015","journal-title":"Presse Med"},{"issue":"10","key":"10.1016\/j.therap.2020.02.011_bib0655","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archinte.163.10.1229","article-title":"Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency","volume":"163","author":"Bork","year":"2003","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.therap.2020.02.011_bib0660","doi-asserted-by":"crossref","first-page":"2421.e1","DOI":"10.1016\/j.joms.2014.08.026","article-title":"Perioperative management of tooth extractions for a patient with hereditary angioedema","volume":"72","author":"Sanuki","year":"2014","journal-title":"J Oral Maxillofac"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0665","doi-asserted-by":"crossref","first-page":"e20152411","DOI":"10.1542\/peds.2015-2411","article-title":"Erythema marginatum as an early symptom of hereditary angioedema: case report of 2 newborns","volume":"137","author":"Martinez-Saguer","year":"2016","journal-title":"Pediatrics"},{"issue":"15","key":"10.1016\/j.therap.2020.02.011_bib0670","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinbiochem.2017.04.007","article-title":"Complement factor C4 activation in patients with hereditary angioedema","volume":"50","author":"Aabom","year":"2017","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0675","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jcp.55.2.145","article-title":"A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency","volume":"55","author":"Gompels","year":"2002","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0680","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaip.2016.12.032","article-title":"Diagnosis, course, and management of angioedema in patients with acquired c1-inhibitor deficiency","volume":"5","author":"Zanichelli","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"33","key":"10.1016\/j.therap.2020.02.011_bib0685","doi-asserted-by":"crossref","first-page":"e4363","DOI":"10.1097\/MD.0000000000004363","article-title":"A nationwide study of acquired C1-inhibitor deficiency in France: characteristics and treatment responses in 92 patients","volume":"95","author":"Gobert","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.therap.2020.02.011_bib0690","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/all.13384","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014The 2017 revision and update","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.therap.2020.02.011_bib0695","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14728222.2019.1608949","article-title":"Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets","volume":"23","author":"Farkas","year":"2019","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0700","doi-asserted-by":"crossref","first-page":"e53773","DOI":"10.1371\/journal.pone.0053773","article-title":"Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment","volume":"8","author":"Maurer","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0705","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.anai.2013.06.021","article-title":"Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks","volume":"111","author":"Craig","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0710","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.jaip.2016.04.018","article-title":"Safety and usage of C1-inhibitor in hereditary angioedema: berinert registry data","volume":"4","author":"Riedl","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.therap.2020.02.011_bib0715","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJMoa0906393","article-title":"Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema","volume":"363","author":"Cicardi","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.therap.2020.02.011_bib0720","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","article-title":"Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors","volume":"110","author":"Makani","year":"2012","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0725","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF03261835","article-title":"Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis","volume":"12","author":"Caldeira","year":"2012","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.therap.2020.02.011_bib0730","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jemermed.2017.05.037","article-title":"Novel Therapies for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review of current evidence","volume":"53","author":"Riha","year":"2017","journal-title":"J Emerg Med"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0735","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/0194599817737974","article-title":"Pharmacotherapy for angiotensin-converting enzyme inhibitor-induced angioedema: a systematic review","volume":"158","author":"Lawlor","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0740","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.revmed.2012.12.017","article-title":"Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema","volume":"34","author":"Nosbaum","year":"2013","journal-title":"Rev Med Interne"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.annemergmed.2018.01.053","article-title":"Specialist advice support for management of severe hereditary angioedema attacks: a multicenter cluster-randomized controlled trial","volume":"72","author":"Javaud","year":"2018","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.therap.2020.02.011_bib0750","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1710-1492-6-16","article-title":"Factor XII mutations, estrogen-dependent inherited angioedema, and related conditions","volume":"6","author":"Binkley","year":"2010","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0755","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.therap.2020.02.011_bib0760","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/nat.2018.0754","article-title":"IONIS-PKKRx a novel antisense inhibitor of prekallikrein and bradykinin production","volume":"29","author":"Ferrone","year":"2019","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"10.1016\/j.therap.2020.02.011_bib0765","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.jaci.2018.06.014","article-title":"Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation","volume":"142","author":"Cao","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.therap.2020.02.011_bib0770","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/all.13582","article-title":"Gene therapy for C1 esterase inhibitor deficiency in a murine model of hereditary angioedema","volume":"74","author":"Qiu","year":"2019","journal-title":"Allergy"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595720300160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:19Z","timestamp":1758567199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595720300160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0040595720300160"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.011","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on bradykinin-mediated angioedema in 2020","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}